DaVita Inc. (NYSE:DVA) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of DaVita Inc. (NYSE:DVA) by 28.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,657 shares of the company’s stock after buying an additional 21,205 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in DaVita were worth $10,021,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its stake in shares of DaVita by 1.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock worth $1,426,000 after acquiring an additional 153 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new position in DaVita in the fourth quarter valued at $2,831,000. Raymond James & Associates increased its stake in shares of DaVita by 135.2% during the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock worth $3,601,000 after buying an additional 19,759 shares during the period. Nisa Investment Advisors LLC increased its position in shares of DaVita by 27.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company’s stock valued at $5,341,000 after purchasing an additional 11,097 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of DaVita by 2,178.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock worth $11,379,000 after purchasing an additional 103,856 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is available through this link. In other DaVita news, COO Michael David Staffieri sold 29,488 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the transaction, the chief operating officer now owns 37,687 shares in the company, valued at approximately $4,515,279.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock worth $16,551,071 over the last quarter. 1.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on DVA. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Truist Financial lifted their target price on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a report on Tuesday, February 20th. Finally, Barclays initiated coverage on DaVita in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Price Performance

DaVita stock opened at $127.82 on Friday. The firm has a fifty day moving average of $130.68 and a 200-day moving average of $109.02. The firm has a market capitalization of $11.21 billion, a P/E ratio of 17.27, a PEG ratio of 1.12 and a beta of 1.04. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $141.54. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. DaVita’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.11 EPS. As a group, analysts predict that DaVita Inc. will post 9.23 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.